Continual-G Highlights Glutathione's Role in Neurodegenerative Diseases, Positions Glyteine® as Key Solution

Event summary

  • A January 2026 review in Frontiers in Pharmacology linked glutathione depletion to neurodegenerative diseases like MS, Parkinson's, and Alzheimer's.
  • Continual-G's parent company, Inid Research Lab, argues traditional glutathione supplements are ineffective for boosting cellular levels.
  • Continual-G's proprietary ingredient Glyteine®, a precursor to glutathione, bypasses regulatory controls to boost cellular glutathione levels.
  • Continual-G was launched in 2019 and focuses on developing supplements incorporating Glyteine®.

The big picture

The growing body of research linking glutathione depletion to neurodegenerative diseases positions Continual-G's Glyteine® as a potential key player in preventive healthcare. The company's focus on bioavailable glutathione precursors aligns with broader industry trends toward cellular health and targeted nutritional interventions. Continual-G's ability to differentiate its product in a competitive market will be crucial for its long-term success.

What we're watching

Clinical Validation
How Continual-G's claims about Glyteine®'s bioavailability will be validated through further clinical studies.
Market Differentiation
Whether Continual-G can sustain its competitive edge in a crowded nutraceuticals market.
Regulatory Scrutiny
The pace at which regulatory bodies may scrutinize claims about glutathione's role in neurodegenerative diseases.